$ALKS Recent News Despite Fed concerns, technica
Post# of 144482
Posted On: 01/16/2014 7:53:45 PM
$ALKS Recent News
Despite Fed concerns, technicals support bull case 1:16 p.m. Sept. 17, 2013 - Michael Ashbaugh
Despite Fed concerns, technicals support bull case 12:02 p.m. Sept. 17, 2013 - Michael Ashbaugh
Biogen, InterMune, Alkermes all make stock waves with earnings 1:28 p.m. July 25, 2013 - Russ Britt
Reading the fine print turns initial Alkermes share loss into a gain 10:49 a.m. May 23, 2013 - Russ Britt
Health stocks ride potential, momentum to a higher close 3:37 p.m. April 19, 2013 - Russ Britt
Alkermes shares surge on positive results for depression disorder drug 12:20 p.m. April 17, 2013 - Russ Britt
S&P, Dow hold tightly to resistance 11:04 a.m. Oct. 8, 2012 - Michael Ashbaugh
Stocks to watch Thursday: Alkermes, Tilly’s 5:42 a.m. May 31, 2012 - MarketWatch
Amylin rallies 20% on diabetes drug approval 11:18 a.m. Jan. 30, 2012 - Val Brickates Kennedy
U.S. futures lower; Pep Boys, Thomas & Betts gain 9:30 a.m. Jan. 30, 2012 - Kate Gibson
PharMerica dives, Amylin surges after hours 7:11 p.m. Jan. 27, 2012 - Carla Mozee
Stocks to Watch Monday: Alkermes, Amylin 6:10 p.m. Jan. 27, 2012 - David B. Wilkerson
FDA approves Amylin's Bydureon diabetes drug 5:56 p.m. Jan. 27, 2012 - MarketWatch.com
Alkermes resumes trading, up 4.7% after hours 4:19 p.m. Jan. 27, 2012 - Carla Mozee
Amylin shares resume trading, up 15% after hours 4:16 p.m. Jan. 27, 2012 - Carla Mozee
FDA approves Alkermes/Amylin drug Bydureon 4:06 p.m. Jan. 27, 2012 - Val Brickates Kennedy
Amlyin, Alkermes to resume trade at 4:15 p.m. EST 4:01 p.m. Jan. 27, 2012 - Carla Mozee
FDA approves Alkermes/Amylin diabetes drug 3:54 p.m. Jan. 27, 2012 - Val Brickates Kennedy
Alkermes, Amylin halted as FDA deadline approaches 2:17 p.m. Jan. 27, 2012 - Val Brickates Kennedy
Amylin, Alkermes shares halted pending news 2:05 p.m. Jan. 27, 2012 - Wallace Witkowski
Cramer's Mad Money - The Best Mad Money Pick Ever (1/14/14) 6:33 a.m. Jan. 15, 2014 - Seeking Alpha
Jim Cramer's Top Stock Picks: HAIN REGN WAG ALKS 6:00 a.m. Jan. 15, 2014 - TheStreet.com
Jim Cramer's 'Mad Money' Recap: Faith in the Market 8:23 p.m. Jan. 14, 2014 - TheStreet.com
J.P. Morgan Healthcare Confab Live Blog: Day Two 10:29 a.m. Jan. 14, 2014 - TheStreet.com
Insider Trading Alert - CFN, INFN, RGR, GLUU And ALKS Traded By Insiders 11:28 a.m. Jan. 13, 2014 - TheStreet.com
Is This the Top for Alkermes Plc (ALKS)? - Tale of the Tape 8:31 a.m. Jan. 9, 2014 - Zacks.com
J.P. Morgan Top Biotechnology Stocks to Buy for 2014 7:39 a.m. Jan. 8, 2014 - 247WallSt.com
Alkermes Announces Advances in Late-Stage CNS Pipeline 6:02 a.m. Jan. 8, 2014 - benzinga.com
Notice of Allowance Received by Alkermes - Analyst Blog 4:21 p.m. Jan. 7, 2014 - Zacks.com
Alkermes Receives Notice of Allowance of US Patent for Novel Fumarate Prodrug for MS 6:04 a.m. Jan. 6, 2014 - benzinga.com
Analysts Issue Bullish Biotech Outlooks for '14, Except Goldman, Which Is Negative 6:03 a.m. Jan. 6, 2014 - TheStreet.com
Insider Trading Alert - UNP, FIS, JBL, MAT And ALKS Traded By Insiders 10:01 a.m. Dec. 30, 2013 - TheStreet.com
Alkermes: 7 Different Insiders Have Sold Shares This Month 2:45 a.m. Dec. 30, 2013 - Seeking Alpha
Alkermes Larger Than S&P 500 Component Legg Mason 4:38 p.m. Dec. 27, 2013 - TheStreet.com
Ireland Home To Several Fast Growing Health Care Names 4:02 p.m. Dec. 24, 2013 - Investors Business Daily
Alkermes plc (ALKS): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report 7:00 a.m. Dec. 16, 2013 - Zacks.com
Alkermes Presents Data on Aripiprazole Lauroxil and ALKS 5461 at 52nd Annual ACNP Meeting 6:13 a.m. Dec. 9, 2013 - benzinga.com
3 Stocks Dragging In The Health Care Sector 12:06 p.m. Dec. 5, 2013 - TheStreet.com
Analysts Actions: ALKS CELG HK ORCL S 8:11 a.m. Dec. 5, 2013 - TheStreet.com
Pharma & Biotech Stock Outlook - Dec 2013 - Industry Outlook 4:28 a.m. Dec. 3, 2013 - Zacks.com
Invesco Perpetual Funds to Make $250 Million Direct Investment in Alkermes’ Ordinary Shares 7:00 a.m. Jan. 13, 2014 - BusinessWire - BZX
Technical Dossier: Theravance, Alkermes, Cubist Pharma, and TherapeuticsMD 8:00 a.m. Jan. 8, 2014 - PR Newswire
Alkermes Announces Advances With Its Late-Stage CNS Pipeline 7:00 a.m. Jan. 8, 2014 - BusinessWire
Alkermes' Corporate Presentation to be Webcast at the 32nd Annual J.P. Morgan Healthcare Conference 4:00 p.m. Jan. 7, 2014 - BusinessWire
Alkermes Announces Notice of Allowance of U.S. Patent for a Novel Fumarate Prodrug for Multiple Sclerosis 7:00 a.m. Jan. 6, 2014 - BusinessWire
FDA Consents, Pending Acquisition Approvals, Program Deployments, and Stock Movements - Research Report on Gilead, Elan, Agilent, Alkermes and Hospira 8:00 a.m. Dec. 18, 2013 - PR Newswire
Morning Research Covering Healthcare Sector: Hospira, Alkermes, Theravance, and Celsion 12:24 p.m. Dec. 10, 2013 - PR Newswire
Alkermes Presents Data on Two Late-Stage Clinical Candidates, Aripiprazole Lauroxil and ALKS 5461, at 52nd Annual ACNP Meeting 7:00 a.m. Dec. 9, 2013 - BusinessWire
Stock Price Movement and Senior Notes Redemption - Research Report on Valeant, Edwards Lifesciences, Alkermes, Mallinckrodt, and Dr. Reddy's 8:00 a.m. Dec. 6, 2013 - PR Newswire
Approved Acquisition, FDA Approvals, Senior Note Offerings, and Announcements by Drug Delivery Companies - Research Report on Elan, IntelliPharmaCeutics, Valeant Pharmaceuticals, Hospira, and Alkermes 8:00 a.m. Nov. 22, 2013 - PR Newswire
Before the Bell Scans: Theravance Inc., Alkermes PLC, Celsion Corp., and Hospira Inc. 6:23 p.m. Nov. 14, 2013 - PR Newswire
Acquisitions, Clinical Trial Results and Stock Price Movements - Research Report on ViroPharma, Pfizer, Alkermes, Tenet, and ResMed 8:00 a.m. Nov. 14, 2013 - PR Newswire
Advancing Pipelines, Liquidity Growth, Cost-reduction Initiatives and Breakthrough Studies - Research Report on Alkermes, Abiomed, Gentium, Amarin, and VIVUS 8:00 a.m. Nov. 6, 2013 - PR Newswire
Alkermes' Corporate Presentation to be Webcast at the Credit Suisse 2013 Healthcare Conference 4:00 p.m. Nov. 5, 2013 - BusinessWire
Alkermes plc Reports Financial Results for Quarter Ended Sept. 30, 2013 6:00 a.m. Oct. 31, 2013 - BusinessWire
New Appointments, Upcoming Earnings Releases, Regulatory Approvals, Status Updates and Informative Resources for New Treatment Options - Research Report on Mylan, Alkermes, Salix, Ligand and Hospira 8:31 a.m. Oct. 30, 2013 - PR Newswire
Alkermes to Host Conference Call to Discuss Financial Results for Quarter Ended Sept. 30, 2013 3:00 p.m. Oct. 24, 2013 - BusinessWire
Pre-Market Review: Alkermes PLC, Hospira Inc., Celsion Corp., and Theravance Inc. 8:30 a.m. Oct. 24, 2013 - PR Newswire
Alkermes Receives Fast Track Designation for ALKS 5461 for Major Depressive Disorder 6:00 a.m. Oct. 10, 2013 - BusinessWire
Alkermes Announces Alignment with FDA on Plans for Pivotal Program for ALKS 5461 for Major Depressive Disorder 6:00 a.m. Oct. 9, 2013 - BusinessWire
Despite Fed concerns, technicals support bull case 1:16 p.m. Sept. 17, 2013 - Michael Ashbaugh
Despite Fed concerns, technicals support bull case 12:02 p.m. Sept. 17, 2013 - Michael Ashbaugh
Biogen, InterMune, Alkermes all make stock waves with earnings 1:28 p.m. July 25, 2013 - Russ Britt
Reading the fine print turns initial Alkermes share loss into a gain 10:49 a.m. May 23, 2013 - Russ Britt
Health stocks ride potential, momentum to a higher close 3:37 p.m. April 19, 2013 - Russ Britt
Alkermes shares surge on positive results for depression disorder drug 12:20 p.m. April 17, 2013 - Russ Britt
S&P, Dow hold tightly to resistance 11:04 a.m. Oct. 8, 2012 - Michael Ashbaugh
Stocks to watch Thursday: Alkermes, Tilly’s 5:42 a.m. May 31, 2012 - MarketWatch
Amylin rallies 20% on diabetes drug approval 11:18 a.m. Jan. 30, 2012 - Val Brickates Kennedy
U.S. futures lower; Pep Boys, Thomas & Betts gain 9:30 a.m. Jan. 30, 2012 - Kate Gibson
PharMerica dives, Amylin surges after hours 7:11 p.m. Jan. 27, 2012 - Carla Mozee
Stocks to Watch Monday: Alkermes, Amylin 6:10 p.m. Jan. 27, 2012 - David B. Wilkerson
FDA approves Amylin's Bydureon diabetes drug 5:56 p.m. Jan. 27, 2012 - MarketWatch.com
Alkermes resumes trading, up 4.7% after hours 4:19 p.m. Jan. 27, 2012 - Carla Mozee
Amylin shares resume trading, up 15% after hours 4:16 p.m. Jan. 27, 2012 - Carla Mozee
FDA approves Alkermes/Amylin drug Bydureon 4:06 p.m. Jan. 27, 2012 - Val Brickates Kennedy
Amlyin, Alkermes to resume trade at 4:15 p.m. EST 4:01 p.m. Jan. 27, 2012 - Carla Mozee
FDA approves Alkermes/Amylin diabetes drug 3:54 p.m. Jan. 27, 2012 - Val Brickates Kennedy
Alkermes, Amylin halted as FDA deadline approaches 2:17 p.m. Jan. 27, 2012 - Val Brickates Kennedy
Amylin, Alkermes shares halted pending news 2:05 p.m. Jan. 27, 2012 - Wallace Witkowski
Cramer's Mad Money - The Best Mad Money Pick Ever (1/14/14) 6:33 a.m. Jan. 15, 2014 - Seeking Alpha
Jim Cramer's Top Stock Picks: HAIN REGN WAG ALKS 6:00 a.m. Jan. 15, 2014 - TheStreet.com
Jim Cramer's 'Mad Money' Recap: Faith in the Market 8:23 p.m. Jan. 14, 2014 - TheStreet.com
J.P. Morgan Healthcare Confab Live Blog: Day Two 10:29 a.m. Jan. 14, 2014 - TheStreet.com
Insider Trading Alert - CFN, INFN, RGR, GLUU And ALKS Traded By Insiders 11:28 a.m. Jan. 13, 2014 - TheStreet.com
Is This the Top for Alkermes Plc (ALKS)? - Tale of the Tape 8:31 a.m. Jan. 9, 2014 - Zacks.com
J.P. Morgan Top Biotechnology Stocks to Buy for 2014 7:39 a.m. Jan. 8, 2014 - 247WallSt.com
Alkermes Announces Advances in Late-Stage CNS Pipeline 6:02 a.m. Jan. 8, 2014 - benzinga.com
Notice of Allowance Received by Alkermes - Analyst Blog 4:21 p.m. Jan. 7, 2014 - Zacks.com
Alkermes Receives Notice of Allowance of US Patent for Novel Fumarate Prodrug for MS 6:04 a.m. Jan. 6, 2014 - benzinga.com
Analysts Issue Bullish Biotech Outlooks for '14, Except Goldman, Which Is Negative 6:03 a.m. Jan. 6, 2014 - TheStreet.com
Insider Trading Alert - UNP, FIS, JBL, MAT And ALKS Traded By Insiders 10:01 a.m. Dec. 30, 2013 - TheStreet.com
Alkermes: 7 Different Insiders Have Sold Shares This Month 2:45 a.m. Dec. 30, 2013 - Seeking Alpha
Alkermes Larger Than S&P 500 Component Legg Mason 4:38 p.m. Dec. 27, 2013 - TheStreet.com
Ireland Home To Several Fast Growing Health Care Names 4:02 p.m. Dec. 24, 2013 - Investors Business Daily
Alkermes plc (ALKS): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report 7:00 a.m. Dec. 16, 2013 - Zacks.com
Alkermes Presents Data on Aripiprazole Lauroxil and ALKS 5461 at 52nd Annual ACNP Meeting 6:13 a.m. Dec. 9, 2013 - benzinga.com
3 Stocks Dragging In The Health Care Sector 12:06 p.m. Dec. 5, 2013 - TheStreet.com
Analysts Actions: ALKS CELG HK ORCL S 8:11 a.m. Dec. 5, 2013 - TheStreet.com
Pharma & Biotech Stock Outlook - Dec 2013 - Industry Outlook 4:28 a.m. Dec. 3, 2013 - Zacks.com
Invesco Perpetual Funds to Make $250 Million Direct Investment in Alkermes’ Ordinary Shares 7:00 a.m. Jan. 13, 2014 - BusinessWire - BZX
Technical Dossier: Theravance, Alkermes, Cubist Pharma, and TherapeuticsMD 8:00 a.m. Jan. 8, 2014 - PR Newswire
Alkermes Announces Advances With Its Late-Stage CNS Pipeline 7:00 a.m. Jan. 8, 2014 - BusinessWire
Alkermes' Corporate Presentation to be Webcast at the 32nd Annual J.P. Morgan Healthcare Conference 4:00 p.m. Jan. 7, 2014 - BusinessWire
Alkermes Announces Notice of Allowance of U.S. Patent for a Novel Fumarate Prodrug for Multiple Sclerosis 7:00 a.m. Jan. 6, 2014 - BusinessWire
FDA Consents, Pending Acquisition Approvals, Program Deployments, and Stock Movements - Research Report on Gilead, Elan, Agilent, Alkermes and Hospira 8:00 a.m. Dec. 18, 2013 - PR Newswire
Morning Research Covering Healthcare Sector: Hospira, Alkermes, Theravance, and Celsion 12:24 p.m. Dec. 10, 2013 - PR Newswire
Alkermes Presents Data on Two Late-Stage Clinical Candidates, Aripiprazole Lauroxil and ALKS 5461, at 52nd Annual ACNP Meeting 7:00 a.m. Dec. 9, 2013 - BusinessWire
Stock Price Movement and Senior Notes Redemption - Research Report on Valeant, Edwards Lifesciences, Alkermes, Mallinckrodt, and Dr. Reddy's 8:00 a.m. Dec. 6, 2013 - PR Newswire
Approved Acquisition, FDA Approvals, Senior Note Offerings, and Announcements by Drug Delivery Companies - Research Report on Elan, IntelliPharmaCeutics, Valeant Pharmaceuticals, Hospira, and Alkermes 8:00 a.m. Nov. 22, 2013 - PR Newswire
Before the Bell Scans: Theravance Inc., Alkermes PLC, Celsion Corp., and Hospira Inc. 6:23 p.m. Nov. 14, 2013 - PR Newswire
Acquisitions, Clinical Trial Results and Stock Price Movements - Research Report on ViroPharma, Pfizer, Alkermes, Tenet, and ResMed 8:00 a.m. Nov. 14, 2013 - PR Newswire
Advancing Pipelines, Liquidity Growth, Cost-reduction Initiatives and Breakthrough Studies - Research Report on Alkermes, Abiomed, Gentium, Amarin, and VIVUS 8:00 a.m. Nov. 6, 2013 - PR Newswire
Alkermes' Corporate Presentation to be Webcast at the Credit Suisse 2013 Healthcare Conference 4:00 p.m. Nov. 5, 2013 - BusinessWire
Alkermes plc Reports Financial Results for Quarter Ended Sept. 30, 2013 6:00 a.m. Oct. 31, 2013 - BusinessWire
New Appointments, Upcoming Earnings Releases, Regulatory Approvals, Status Updates and Informative Resources for New Treatment Options - Research Report on Mylan, Alkermes, Salix, Ligand and Hospira 8:31 a.m. Oct. 30, 2013 - PR Newswire
Alkermes to Host Conference Call to Discuss Financial Results for Quarter Ended Sept. 30, 2013 3:00 p.m. Oct. 24, 2013 - BusinessWire
Pre-Market Review: Alkermes PLC, Hospira Inc., Celsion Corp., and Theravance Inc. 8:30 a.m. Oct. 24, 2013 - PR Newswire
Alkermes Receives Fast Track Designation for ALKS 5461 for Major Depressive Disorder 6:00 a.m. Oct. 10, 2013 - BusinessWire
Alkermes Announces Alignment with FDA on Plans for Pivotal Program for ALKS 5461 for Major Depressive Disorder 6:00 a.m. Oct. 9, 2013 - BusinessWire
(0)
(0)Scroll down for more posts ▼